Simcere Pharmaceutical Group Limited (HKG:2096)

Hong Kong · Delayed Price · Currency is HKD

11.67

+0.07 (0.60%)

Sep 23, 2026, 4:08 PM HKT

Market Cap	29.79B -10.8%
Revenue (ttm)	10.07B +22.8%
Net Income	1.81B +81.4%
EPS	0.70 +73.0%
Shares Out	2.57B
PE Ratio	16.49
Forward PE	12.74
Dividend	0.21 (1.80%)
Ex-Dividend Date	Jun 17, 2026

Volume	2,766,000
Open	11.61
Previous Close	11.60
Day's Range	11.47 - 11.73
52-Week Range	9.07 - 14.38
Beta	0.72
Analysts	Buy
Price Target	17.67 (+51.41%)
Est. Earnings	Nov 13, 2026

About HKG:2096

Simcere Pharmaceutical Group Limited, an investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products to distributors, pharmacy chains, and other pharmaceutical manufacturers in China. It develops Endostar, a recombinant human endostatin injection; ENWEIDA, an envafolimab injection; Leruiping, a fully human monoclonal antibody targeting IL-4Rα; Zemprocitinib a highly selective JAK1 inhibitor; and Xianlinda, an inhibitor for influenza polymerase acidic protein that has completed Phase 3 clini... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 1995

Employees 7,064

Stock Exchange Hong Kong Stock Exchange

Ticker Symbol 2096

Full Company Profile

Financial Performance

In 2025, HKG:2096's revenue was 7.73 billion, an increase of 16.52% compared to the previous year's 6.64 billion. Earnings were 1.34 billion, an increase of 86.15%.

Financial numbers in CNY Financial Statements

Analyst Summary

According to 6 analysts, the average rating for 2096 stock is "Buy." The 12-month stock price target is $17.67, which is an increase of 51.41% from the latest price.

Price Target

$17.67

(51.41% upside)

Analyst Consensus: Buy

Stock Forecasts